Nav: Home

UA engineers zero in on early detection of ovarian cancer

May 31, 2016

University of Arizona researcher Jennifer Barton is leading a two-year, $1 million project funded by the National Cancer Institute to identify imaging biomarkers of ovarian cancer, the most deadly gynecological cancer in the United States. This work may enable the first effective screening system for ovarian cancer.

"Located deep in the body, with few early symptoms and no effective screening techniques, ovarian cancer has remained stubbornly difficult to understand, much less effectively combat," said Barton, professor of biomedical engineering, electrical and computer engineering, optical sciences, and agricultural and biosystems engineering, and interim director of the UA BIO5 Institute.

In fact, 70 percent of women diagnosed have advanced ovarian cancer that has spread beyond the fallopian tubes and ovaries to other organs, she said.

Tracking an Elusive Enemy

Barton is collaborating with researchers in the UA departments of physiology, medical imaging, and obstetrics and gynecology to identify imaging biomarkers, or subtle changes in the tissue that can be detected by sensitive optical methods, for ovarian cancer in mice. The mice spontaneously develop ovarian tumors and mimic hormonal conditions of postmenopausal women, who are most often diagnosed with the disease.

Using three high-resolution optical imaging techniques -- optical coherence tomography, fluorescence imaging and multiphoton microscopy -- the researchers are obtaining in vivo images of the animals' ovaries and fallopian tubes and analyzing physical and biochemical changes over time to create a roadmap of the changes that happen during ovarian cancer.

"This gives us a very controlled way of looking at ovarian cancer," Barton said. "We can observe developments over just a few months that would occur over several years in women with the disease." The researchers will also develop contrast agents to study overexpression of cell surface receptors that could be targeted to increase sensitivity to imaging.

Opening the Door for Noninvasive Testing

Presently the only way to confirm ovarian cancer is with a surgical biopsy.

"Our goal is to identify biomarkers at the earliest possible stage of ovarian cancer to build a viable optical imaging technology that will enable early detection and save lives," said Barton, previously inaugural head of the College of Engineering biomedical engineering program, chair of the UA biomedical engineering graduate interdisciplinary program and UA associate vice president for research.

"We believe that early in ovarian cancer development, there are clusters of cells in the fallopian tube that have abnormal microstructure and fluorescence," Barton said. "We believe we can detect these cells before they spread to the ovary and cause advanced cancer."

Evan Unger, MD, a UA professor of radiology and bioengineering who with Barton co-leads the Cancer Imaging Program at the Arizona Cancer Center, said the predictive biomarkers will help more accurately stratify women in risk groups for ovarian cancer and "open the door for more intensive screening using a noninvasive or minimally invasive technique like the microendoscope Dr. Barton has developed."

Barton's tiny, highly flexible endoscope, or falloposcope, is a wand-like imaging device that combines several optical imaging techniques to detect ovarian cancer in the fallopian tubes, where many researchers believe the cancer originates. Her team has already tested rigid prototypes in pilot clinical studies, but the new flexible version will not require any incisions, making it more suitable for screening.

Screening Critical for Early Diagnosis, Treatment

Caught early, ovarian cancer can often be treated effectively with surgery and chemotherapy. But with no good tools for catching it early, fewer than half of women diagnosed survive five years.

Women who receive manual exams, pelvic ultrasound or blood tests for the CA-125 protein, which may indicate elevated risk, are no less likely to die from ovarian cancer than women who don't. Further, most women diagnosed have none of the associated risk factors, such as a family history of the disease or mutations of the BRCA genes.

According to the Centers for Disease Control and Prevention, each year approximately 20,000 U.S. women are diagnosed with ovarian cancer and 14,000 die from the disease.

Meredith Mitstifer is one of the lucky ones.

At 30, while visiting a fertility specialist, she had an ultrasound test that revealed a large mass in her left ovary. A few weeks later, preparing for surgery, she learned she was pregnant. She had the diseased ovary removed and biopsied, confirming early stage ovarian cancer. She went on to give birth to Ryan, now a healthy teenager.

Mitstifer, a clinical psychologist for the Federal Bureau of Prisons, is approaching her 14th year with no evidence of disease. She serves on the board of the National Ovarian Cancer Coalition and has participated in Survivors Teaching Students: Saving Women's Lives, an Ovarian Cancer National Alliance program in which ovarian cancer survivors share their stories with UA medical students.

"I've lost many friends to this awful disease, and have many other friends who are dying from it," she said. "Many of them desperately want to see advances in diagnosis and treatment and, ultimately, a cure, so their own children won't have to go through what they have. An effective screening process would be a great start."
-end-
The Tucson chapter of the National Ovarian Cancer Coalition will host its first Walk to Break the Silence on the UA campus on Nov. 6. Contact tucsonaz@ovarian.org for more information.

University of Arizona College of Engineering

Related Ovarian Cancer Articles:

Uncovering the mechanisms that support the spread of ovarian cancer
In this issue of the JCI, research led by Wang Min at Yale University describes how a subtype of macrophages communicate with and support tumor cell growth to drive metastasis in ovarian cancer.
Ovarian cancer study uncovers new biology
In what is believed to be the largest study of its kind, scientists at The Johns Hopkins University and the Pacific Northwest National Laboratory led a study that examined the proteomes of 169 ovarian cancer patients to identify critical proteins expressed by their tumors.
Chemotherapy may boost immunotherapy power in ovarian cancer
Cancer Research UK scientists have found that women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy.
UA engineers zero in on early detection of ovarian cancer
University of Arizona researcher Jennifer Barton is leading a two-year, $1 million project funded by the National Cancer Institute to identify imaging biomarkers of ovarian cancer, the most deadly gynecological cancer in the United States.
Ludwig Cancer Research and CRI initiate clinical trial of immunotherapy for ovarian cancer
Ludwig Cancer Research and the Cancer Research Institute (CRI) have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
Different types of ovarian cancer have different causes
The more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 National Cancer Research Institute Cancer Conference Tuesday.
Researchers isolate possible ovarian cancer biomarkers
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I-IV.
New Stand Up To Cancer-OCRF-OCNA-NOCC Ovarian Cancer Dream Team announced
The Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition $6 milion Ovarian Cancer Dream Team will focus on DNA repair pathways and therapies for ovarian cancer, seeking to expand on the recent clinical advances seen with PARP inhibitors.
Seeking new targets for ovarian cancer treatment
Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute presented today at the American Association for Cancer Research Annual Meeting 2015.
'Patchwork' ovarian cancer more deadly
The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today in PLOS Medicine.

Related Ovarian Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".